drugset / Trial / NCT00278200
Vaccine Therapy For Patients Being Considered For Organ Transplant Who Are at Risk For PTLD
Phase 1
Terminated
23 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI) · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
RATIONALE: Vaccines made from a person's white blood cells may help the body build an effective immune response. PURPOSE: This phase I trial is studying the side effects of vaccine therapy in treating patients who are being considered for solid organ transplant who are at risk for post-transplant lymphoproliferative disorder.
Timeline
- Start
- 2003-01
- Primary completion
- 2012-08
- Completion
- 2012-08
Outcome
Outcome not reported
Stopped (Business): “Loss of funding”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Inactivated EBV-infected vaccine | Vaccine | — | Intravenous |